New treatment approach shows promise in reducing prostate cancer spread
Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an international phase 3 trial.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.